Multiple System Atrophy Clinical Trial
Official title:
A Randomized, Placebo-controlled, Parallel Group, Patient-blind, Phase I Study Assessing the Safety and Exploring the Immunogenicity/Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early Multiple System Atrophy
This is a randomized controlled parallel Group phase I study to investigate the safety and
immunological/ therapeutic activity of two new vaccines, AFFITOPE® PD01A and AFFITOPE®
PD03A, given to patients with early Multiple System Atrophy (MSA).
In total 30 patients are planned to be enrolled in the study: 12 patients in each treatment
arm who will receive either 75µg AFFITOPE® PD01A (with adjuvant) or 75µg AFFITOPE® PD03A
(with adjuvant) and 6 patients in the control group who will receive the reference substance
(Placebo). Over a study duration of 52 weeks, the study participants will receive 4
injections as basic immunization in a 4-weekly interval and 1 boost immunization 36 weeks
after the first injection. Male and female patients aged 30 to 75 years can participate in
the trial. 2 study sites in France (Bordeaux and Toulouse) will be involved.
AFF009 is part of the project SYMPATH funded by the European Commission
(FP7-HEALTH-2013-INNOVATION-1 project; N° HEALTH-F4-2013-602999).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
| Completed |
NCT05788133 -
The Role of Humanoid Robot in Neuropsychological Assessment and Cognitive Training.
|
N/A | |
| Completed |
NCT05080777 -
Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems
|
N/A | |
| Completed |
NCT03295786 -
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04265482 -
Community-based Cohort of Functional Decline in Subjective Cognitive Complaint Elderly
|
||
| Not yet recruiting |
NCT02222779 -
Quantification of Transition Metals
|
N/A | |
| Recruiting |
NCT01291550 -
Electronic Nose for Diagnosis of Neurodegenerative Diseases Via Breath Samples
|
N/A | |
| Completed |
NCT01450891 -
Health Technology Assessment of Diagnostic Approaches in Alzheimer's Disease
|
N/A | |
| Completed |
NCT01953523 -
Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions
|
N/A | |
| Recruiting |
NCT06148233 -
CSF1R PET Probe [18F]CSF-23 in Alzheimer's Disease Brain Imaging
|
N/A | |
| Completed |
NCT03538522 -
A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
|
Phase 2 | |
| Completed |
NCT06251830 -
Increasing Diagnosis Rates While Reducing Examination Time: Can MR Fingerprinting Deliver on Its Promise?
|
||
| Recruiting |
NCT04472130 -
Neurodegenerative Diseases Registry
|
||
| Completed |
NCT03353207 -
Striatal Dopamine Transmission in Individuals With Isolated Rapid Eye Movement Sleep With Atonia: a Search for Precursor Biomarker for Neurodegeneration
|
||
| Completed |
NCT05095870 -
Evaluation of the Peripheral Nerve Ultrasound as a Diagnostic Tool in CANVAS Neuropathies
|
||
| Recruiting |
NCT05784090 -
Correlation Between Melatonin Levels in Different Biological Fluids
|
||
| Completed |
NCT02108769 -
Yogic Breathing Changes Salivary Components
|
N/A | |
| Recruiting |
NCT05508789 -
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
|
Phase 3 | |
| Recruiting |
NCT04820881 -
Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain Injury
|
||
| Recruiting |
NCT05235802 -
Long-term Follow-up in Severe Traumatic Brain Injury
|